Extracted thylakoids regulate gut microbiota by increasing insulin sensitivity and enhancing probiotic adherence to the mucosa.
A Lactobacillus composition inhibits Helicobacter pylori adhesion and invasion through bacterial competition.
Anti-EMR1 antibodies bind the ELD-6 receptor domain to deplete eosinophils, addressing the lack of selective binding in existing therapies.
Hydrated food-grade polymers form non-particulate matrices that sustain warming sensations across the throat without causing stinging.
A subcutaneously implanted pump delivers levodopa and carbidopa using a high-concentration, low-viscosity solvent system.
A polymeric film coating combines water-insoluble polymer and indigestible polysaccharide to control drug release kinetics.
Substituted perhydro pyrrolopyridines decrease viral load to address inadequate sustained response rates and side effects of current therapies.
Specific amino acid substitutions reduce immunogenicity and enable targeted treatment of intestinal fibrosis in severe inflammatory bowel disease.